Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


SparingVision sees to new funding
Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.
V2Food dishes up $55m series B
Main Sequence Ventures, which co-founded the meat-free burger producer last year, has returned for a $55m series B round.
A2 coordinates $71.5m series B
UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.
Walden Biosciences welcomes $51m
Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.
XY spells out $59m series B
Zhejiang University-backed optical chip maker XY Technology will put the series B cash to strengthening its capacity and product.
Mosa Meat starts cooking up series B
Bell Food Group and M Ventures have contributed to an initial $55m series B tranche for the cultured meat developer spun out of Maastricht University.
Monte Rosa climbs $96m series B
University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.
Creative Biosciences designs $88m series C
Creative Biosciences has collected $88m in fresh funding, five years after being founded by a Sun Yat-Sen University professor.

Other News

Galecto gets $64m
A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.
Virogin Biotech transmits $62m series C
Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.
Corporates floor Lava with $83m
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.
Seegrid reframes latest round to $52m
CMU's warehouse vehicle manufacturer Seegrid has more than doubled its latest round to $52m, building on an initial $25m from G2VP six months ago.
Graphite Bio fleshes out $45m series A
Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.
Escape Bio hatches $73m
Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg